January 2019 Supplement - Endovascular Today

Table of Contents

Supplement

January 2019 Supplement

Shifting the SFA Treatment Paradigm

Global thought leaders discuss the ELUVIA DES IMPERIAL Trial results and its influence on treatment decisions

Sponsored by Boston Scientific Corporation

Issue

Pearls & Pitfalls in Vascular Intervention

Experience-based insights for technical success and avoiding complications

View Issue

In This Supplement

Download PDF

IMPERIAL 12-Month Full Cohort and Long Lesion Sub-Study Results

Sustained drug-release in the SFA drives superior results.

By William A. Gray, MD, Additional commentary by Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA, FSIR

A Roundtable Discussion on Results From the First Head-to-Head DES SFA Trial: IMPERIAL

A multidisciplinary panel of PAD experts discuss the impact on patient care and the health care system and how these results may shift current treatment algorithms.

With Michael R. Jaff, DO; Gary M. Ansel, MD, FACC; William A. Gray, MD; Steve Henao, MD, FACC, FACS; and Robert A. Lookstein, MD

Discussing the IMPERIAL Data in Practice

Two vascular experts share their reactions to hearing the results of the first head-to-head peripheral DES trial.

With Yann Gouëffic, MD, PhD; and Andrew Holden, MBChB, FRANZCR, EBIR

Latest Issues

March 2026

February 2026

January 2026

December 2025

November 2025

View All Issues

In This Supplement

Most Read Articles